LungLife AI
Company Profile
Company website
Sector
Pharmaceuticals and Biotechnology (Biotechnology)
Description
LungLife is a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence. The Company’s core technologies are integrated in the LungLB® test, which is intended to be used as a tool to provide physicians with additional information to help in the decision-making process for people with indeterminate lung nodules that may be lung cancer following a CT scan.
Investor Access
08
Aug
Event information
The Company will announce its unaudited half-year results for the six months ended 30 June 2023 on Tuesday 8 August 2023 at 16:30 BST.
Investors can sign up to Investor Meet Company for free and add to meet Lung life AI via the following link: https://www.investormeetcompany.com/lunglife-ai-inc/register-investor
Venue
Online
Time
Tuesday 8 August 2023 at 16:30 BST
Financial Calendar
| Event | Date |
| Year End | 31 December |
| Half Year End | 30 June |
| Preliminary Results* | September |
| Interim Results* | March |
| AGM* | May |
* Months based on previous announcements of this kind
